pharmaceutical · input
PRRSV costs US pork industry ~$664M/year; Boehringer Ingelheim and Zoetis control dominant share of US swine biologicals market; no PRRSV cure exists.
7
Source countries
8
Companies
1
Goods affected
0
Claims on record
What depends on it
1 essential American goods rely on swine vaccines (prrsv, pcv2, mycoplasma) somewhere upstream in their supply chain.
Where it comes from
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| USUnited States | 35% |
| CNChina | 28% |
| DEGermany | 12% |
| FRFrance | 8% |
| NLNetherlands | 3% |
| HUHungary | 2% |
| IEIreland | 2% |
Who makes it
8 companies produce swine vaccines (prrsv, pcv2, mycoplasma).
Merck Animal Health (Madison NJ; division of Merck & Co.; ~$5.5B revenue) manufactures AviPro brand avian influenza and Newcastle disease vaccines for commercial poultry. Products sold as MSD Animal Health outside North America. Merck Animal Health is the third-largest animal health company globally. De Soto KS biologics manufacturing site.
Private German pharmaceutical company. Originator of Spiriva (tiotropium HandiHaler and Respimat), Combivent, and Striverdi. The Respimat Soft Inhaler — a proprietary aqueous mist device — is assembled exclusively at Boehringer microParts GmbH in Dortmund. Doubled Respimat production to 44 million units/year via ~€100M Dortmund expansion.
Zoetis Inc. (NYSE: ZTS; ~$8.5B revenue; Parsippany NJ) is the world's largest animal health company, spun off from Pfizer in 2013. Zoetis manufactures TROVAC-NDV and conventional inactivated AI vaccines for commercial poultry, along with broad-spectrum animal health products for livestock and companion animals across 100 countries.
Global leader in Marek's disease vaccine production and the world's largest producer of poultry vaccines. Its Gainesville, Georgia facility produces approximately 60 billion poultry vaccine doses per year for the US and ~60 other countries — one of the largest single biological manufacturing sites in the world. In 2024, acquired Elanco's US poultry biologics portfolio for $885M, further consolidating leadership. Product portfolio includes HVT-based vaccines, PREVEXXION RN (chimeric Serotype 1, first new MDV1 innovation in 40+ years, approved EU/UK 2021), and the VAXXITEK recombinant HVT vector family. Also a major human pharmaceutical company (Jardiance, Pradaxa, Spiriva, Dupixent collaborator).
Ceva Santé Animale (Libourne, France; private; ~€1.7B revenue) is the 5th largest animal health company globally and a major poultry vaccine manufacturer. Ceva produces MAFIVAC AI vaccines, VECTORMUNE ND+AI recombinant vaccines, and other poultry biologicals. Ceva has significant manufacturing in France (Libourne + Pau), Spain, and the US. In 2022-2024, Ceva supplied emergency AI vaccines to France's commercial duck industry during HPAI H5N1 outbreaks.
State-owned under SASAC; Chinas largest animal vaccine maker; swine vaccines 49.4% of China total animal vaccine sales; 14.3% domestic market share
Major Chinese swine biologics producer; competes domestically and in growing international markets; PRRS and classical swine fever vaccines
Phibro Animal Health Corporation (Teaneck NJ; NASDAQ: PAHC; ~$1B revenue) manufactures POULVAC brand poultry vaccines (acquired from Fort Dodge/Zoetis divestiture) along with medicated feed additives and nutritional products. Phibro serves commercial poultry producers globally with AI vaccines, Newcastle disease biologics, and coccidiostats.
